SEC Form 4	
FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB	APPROVAL

OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre Tingley Whi	1 0	Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Tenaya Therapeutics, Inc.</u> [ TNYA ]		ationship of Reporting (all applicable) Director	10% O	wner
(Last) C/O TENAYA	(First) THERAPEU1	(Middle) TICS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 02/23/2024	X	Officer (give title below) Chief Med	Other ( below) ical Officer	specify
171 OYSTER I	POINT BLVD	., 5TH FLOOR	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group		
(Street) SOUTH SAN FRANCISCO	СА	94080			Form filed by More Person		
			Rule 10b5-1(c) Transaction Indication				
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a the affirmative defense conditions of Rule 10b5-1(c). See Instruction		instruction or written pla	n that is intended	to satisfy
		Table I - Non-D	erivative Securities Acquired, Disposed of, or Benef	icially (	Dwned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
	Code V			v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(mau. 4)
Common Stock <sup>(1)</sup>	02/23/2024 <sup>(2)</sup>		A		35,000	Α	\$ <mark>0</mark>	108,534(3)	D	

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

				-				-							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		5. Numbo Derivativ Securitie Acquired or Dispo of (D) (In 3, 4 and	re s I (A) sed str.	6. Date Exercia Expiration Dat (Month/Day/Ye	on Date of Securities		8. Price of Derivative Security (Instr. 5) Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to buy)	\$5.22	02/23/2024		A		215,000		03/23/2024 <sup>(4)</sup>	02/22/2034	Common Stock	215,000	\$0	215,000	D	

## Explanation of Responses:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock.

2. The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2024, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. 3. Includes 83,750 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

4. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested.

<u>/s/ Jennifer Drimmer Rokovich</u> , <u>Attorney in Fact</u>	02/27/2024
** Signature of Reporting Person	Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.